About TRANSCENTA-B Company

We are a clinical-stage biopharmaceutical company with comprehensive capabilities to discover, research, develop, and manufacture differentiated antibody drugs for treatment areas where there is a huge gap in medical demand, including tumors, kidney disease, and skeletal diseases. Our management team and main business (including clinical development, regulatory entry and business development) are located in the US and China, while our discovery, R&D, process development and production teams are all located in China. Since our inception, we have been committed to global strategy and vision. We strive to develop molecules with global intellectual property rights and design and conduct multi-regional clinical trials to meet domestic and international regulatory requirements, which will help create a global commercial channel for our products. We have developed an antibody discovery platform with a unique function, the Immune Tolerance Breakthrough (IMTB) technology platform, which enables us to build a diversified and risk-balanced antibody product pipeline with best-in-class or first-of-its-kind potential. With the help of this IMTB technology platform, we have discovered and developed 9 out of 10 candidate antibodies internally, enabling us to generate antibodies that are difficult to discover through traditional platforms, and help us select candidate molecules with better pharmacogenicity and high commercial potential. TST001 (our key project, with best-in-class potential) is a high-affinity humanized antibody that specifically targets Claudin 18.2. This target is overexpressed in a variety of cancers, including gastric cancer or gastroesophageal junction cancer, pancreatic cancer, biliary tract cancer, and other types of solid tumors. TST001 is currently preparing to conduct critical global tests, pending review by regulators of favorable data on its efficacy, safety, and tolerability. All of the molecules we are currently developing have a comprehensive set of translational research strategies to achieve their full clinical and commercial potential. By enhancing the role of translational science, we can better understand disease biology to design and conduct our clinical studies, and support us in identifying the right patient groups to improve the chances of trial success. We have established a fully integrated CMC functional department with full capabilities from developability assessment, cell line development, process and analytical development to DS and DPGMP production, and have established comprehensive QA, QC and quality management systems to meet production needs and ensure stable high-quality products. Since 2018, our T-BLOC facility has been producing cell banks, DS, and DP for toxicology studies, phase I, phase II, and phase III clinical trials for internal and external projects. Our proprietary integrated continuous flow bioprocessing (“ICB”) platform has demonstrated industry-leading volumetric productivity, enabling us to reduce production costs while maximizing output. Through our integrated continuous flow bioprocessing platform, we have achieved the best productivity in the industry of over 6g/L per day, and the productivity is more than 10 times higher than traditional flow processing technology. With our industry-leading CMC capabilities, we also provide high-quality CDMO services and generate cash flow to our growing customer base. Cooperation and collaboration are an important part of our strategy. Our differentiated products and cutting-edge technology platforms provide leverage and flexibility in how we structure partnerships. We have made significant progress in discussions with a range of potential partners who can provide a broad range of commercial infrastructure to bring our projects to various markets. Our core management team members have an average of over 15 years of experience, an outstanding track record, and balanced expertise in research, clinical development, manufacturing, planning and financing. Our shareholders include global and Chinese professional funds focused on biotechnology and biopharmaceutical platforms experienced in supporting and developing biopharmaceutical companies. As a result, we will benefit from their industry expertise and resources. Our experienced team, fully integrated capabilities, and differentiated yet risk-balanced product lines are the cornerstones of our mission to discover, develop, and deliver innovative, affordable medicines to help patients around the world.